Bristol-Myers Squibb completes acquisition of iPierian Bristol-Myers Squibb Organization and iPierian, Inc. Announced today that Bristol-Myers Squibb has obtained iPierian, a privately held biotechnology company focused on the development and discovery of new treatments for Tauopathies, a course of neurodegenerative diseases associated with the pathological aggregation of Tau proteins in the mind. The acquisition gives Bristol-Myers Squibb full rights to iPierian's lead asset IPN007, a forward thinking preclinical monoclonal antibody that represents a promising new approach to treat progressive supranuclear palsy and other Tauopathies, and gets the potential to commence Stage 1 clinical trials by early 2015 buy dapoxetine online .
The funding is part of Delivering Hope, an umbrella program for Bristol-Myers Squibb’s initiatives in the areas of hepatitis awareness, care and prevention. Organizations receiving funding are: The Liver Disease Prevention and Treatment Analysis Foundation will generate a training program for sufferers and community-based health care providers in detection, care, and management of individuals and provide usage of treatment in remote control areas. The Liver Basis/West Bengal will conduct a survey of the influence of liver disease and hepatitis C and utilize the findings to inform public health plan and foster prevention and awareness activities in at risk populations.